Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

24 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
High MET Overexpression Does Not Predict the presence of MET exon 14 Splice Mutations in NSCLC: Results From the IFCT PREDICT.amm study.
Baldacci S, Figeac M, Antoine M, Descarpentries C, Kherrouche Z, Jamme P, Copin MC, Tulasne D, Nanni I, Beau-Faller M, Melaabi S, Levallet G, Quoix E, Moro-Sibilot D, Friard S, Missy P, Barlesi F, Cadranel J, Cortot AB. Baldacci S, et al. Among authors: descarpentries c. J Thorac Oncol. 2020 Jan;15(1):120-124. doi: 10.1016/j.jtho.2019.09.196. Epub 2019 Oct 9. J Thorac Oncol. 2020. PMID: 31605799 Free article.
Exon 14 Deleted MET Receptor as a New Biomarker and Target in Cancers.
Cortot AB, Kherrouche Z, Descarpentries C, Wislez M, Baldacci S, Furlan A, Tulasne D. Cortot AB, et al. Among authors: descarpentries c. J Natl Cancer Inst. 2017 May 1;109(5). doi: 10.1093/jnci/djw262. J Natl Cancer Inst. 2017. PMID: 28376232 Review.
Alterations in the PI3K Pathway Drive Resistance to MET Inhibitors in NSCLC Harboring MET Exon 14 Skipping Mutations.
Jamme P, Fernandes M, Copin MC, Descarpentries C, Escande F, Morabito A, Grégoire V, Jamme M, Baldacci S, Tulasne D, Kherrouche Z, Cortot AB. Jamme P, et al. Among authors: descarpentries c. J Thorac Oncol. 2020 May;15(5):741-751. doi: 10.1016/j.jtho.2020.01.027. Epub 2020 Mar 10. J Thorac Oncol. 2020. PMID: 32169477 Free article. Review.
Response to Capmatinib in a MET Fusion-positive Cholangiocarcinoma.
Turpin A, Descarpentries C, Grégoire V, Farchi O, Cortot AB, Jamme P. Turpin A, et al. Among authors: descarpentries c. Oncologist. 2023 Jan 18;28(1):80-83. doi: 10.1093/oncolo/oyac194. Oncologist. 2023. PMID: 36434677 Free PMC article.
MET exon 14 skipping mutation is a hepatocyte growth factor (HGF)-dependent oncogenic driver in vitro and in humanised HGF knock-in mice.
Fernandes M, Hoggard B, Jamme P, Paget S, Truong MJ, Grégoire V, Vinchent A, Descarpentries C, Morabito A, Stanislovas J, Farage E, Meneboo JP, Sebda S, Bouchekioua-Bouzaghou K, Nollet M, Humez S, Perera T, Fromme P, Grumolato L, Figeac M, Copin MC, Tulasne D, Cortot AB, Kermorgant S, Kherrouche Z. Fernandes M, et al. Among authors: descarpentries c. Mol Oncol. 2023 Nov;17(11):2257-2274. doi: 10.1002/1878-0261.13397. Epub 2023 Jul 14. Mol Oncol. 2023. PMID: 36799689 Free PMC article.
24 results